Market Cap 532.79M
Revenue (ttm) 0.00
Net Income (ttm) -83.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 70,200
Avg Vol 238,506
Day's Range N/A - N/A
Shares Out 37.44M
Stochastic %K 36%
Beta -0.34
Analysts Strong Sell
Price Target $39.50

Company Profile

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORK...

Industry: Biotechnology
Sector: Healthcare
Phone: (650) 606-7910
Website: orukatx.com
Address:
855 Oak Grove Avenue, Suite 100, Menlo Park, United States
Quantumup
Quantumup Jul. 23 at 6:25 PM
H.C. Wainwright reit'd $ORKA Buy/$45 after Oruka📰that the FDA had cleared its IND application for its Phase 2a trial of ORKA-001 (the company's long-acting anti-IL-23p19 antibody) in moderate-to-severe PsO, called EVERLAST-A. $ABBV $PTGX - $JNJ #EDAV25 H.C. Wainwright said in its note: "This program is a randomized, double-blind, placebo-controlled Phase 2a trial designed to evaluate the safety and efficacy of a single dose level of ORKA-001 in moderate-to-severe psoriasis patients. EVERLAST-A will enroll approximately 80 patients, randomized 3:1 to receive ORKA-001 or matching placebo. The primary endpoint is PASI 100 at Week 16. ORKA-001 exposures are expected to match or exceed exposures in the KNOCKOUT study, providing a definitive test of whether higher exposures of an anti-IL-23p19 antibody can lead to greater efficacy. H.C. Wainwright went on to say:
0 · Reply
Quantumup
Quantumup Jul. 21 at 1:15 PM
Stifel reiterated $ORKA Buy-$47 after $ORKA's disclosure of the IND clearance for ORKA-001 and then catching up w/ mgmt.. $ABBV $PTGX $JNJ #EADV25 UCBJY $MLTX Stifel said in its note: "We caught up with management who noted that the IND clearance was based on interim Ph1 data (safety/tolerability) and Ph2a sites are open and actively enrolling -- Ph1 results to be presented at #EADV in September. Recall, ORKA-001 is a next-gen IL-23p19 which is designed to explore greater exposure and improved dosing vs. mega-blockbuster Skyrizi based on exploratory IST results in Psoriasis demonstrating superior efficacy/potential for remission in patients dosed with 4x the normal psoriasis dose (LINK). Meanwhile, $ORKA is on track to release Ph1 data for ORKA-002 (next-gen IL-17A/F mAb) by YE25 following a continued strong launch for Bimzelx and upcoming Ph3 data for $MLTX's sonelokimab -- there is currently limited investor focus on $ORKA as a player in the IL-17A/F space."
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 21 at 11:57 AM
$ORKA (+7.3% pre) Oruka Therapeutics Announces IND Clearance for EVERLAST-A - GN https://ooc.bz/l/70552
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 21 at 11:15 AM
$ORKA pt 17+
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 21 at 11:14 AM
$ORKA Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September By Oruka Therapeutics, Inc. | July 21, 2025, 7:00 AM
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 18 at 11:01 AM
$ORKA will need u 2 both today ! $SLS for the moves for stocks moving as we go through this !
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 18 at 11:00 AM
$BZAI coding off this 6.56 6.62 6.64 $SLS isolating now $ORKA indirectly cut an pasting old abio movement with 7.1-7.12 7.23* portions of old abio. @zsk78 u remember my abio dont u ? the pop but also the short !
0 · Reply
jlwnh
jlwnh Jul. 9 at 5:30 PM
$ORKA thants my boy!!!…
0 · Reply
Pika_Capital
Pika_Capital Jul. 9 at 5:18 PM
$ARWR $VRDN $ORKA $SYRE Pika's dumpster diving was quite successful 🤿
1 · Reply
jlwnh
jlwnh Jul. 8 at 2:27 PM
$ORKA hidden gem here…
0 · Reply
Latest News on ORKA
Oruka Therapeutics Announces $200 Million Private Placement

Sep 12, 2024, 7:05 AM EDT - 11 months ago

Oruka Therapeutics Announces $200 Million Private Placement


Arca Biopharma stock ($ABIO) soars on merger news

Apr 3, 2024, 11:38 AM EDT - 1 year ago

Arca Biopharma stock ($ABIO) soars on merger news


ARCA biopharma Announces 2023 Financial Results

Feb 1, 2024, 4:35 PM EST - 1 year ago

ARCA biopharma Announces 2023 Financial Results


ARCA biopharma Announces Third Quarter 2023 Financial Results

Oct 18, 2023, 4:25 PM EDT - 1 year ago

ARCA biopharma Announces Third Quarter 2023 Financial Results


ARCA biopharma Announces Second Quarter 2023 Financial Results

Jul 21, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces Second Quarter 2023 Financial Results


ARCA biopharma Announces First Quarter 2023 Financial Results

Apr 24, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces First Quarter 2023 Financial Results


James Flynn Joins ARCA biopharma Board of Directors

Dec 19, 2022, 4:05 PM EST - 2 years ago

James Flynn Joins ARCA biopharma Board of Directors


ARCA biopharma Announces Third Quarter 2022 Financial Results

Oct 28, 2022, 4:15 PM EDT - 2 years ago

ARCA biopharma Announces Third Quarter 2022 Financial Results


Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

Jun 21, 2022, 4:05 PM EDT - 3 years ago

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors


ARCA biopharma Announces First Quarter 2022 Financial Results

May 2, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Announces First Quarter 2022 Financial Results


Quantumup
Quantumup Jul. 23 at 6:25 PM
H.C. Wainwright reit'd $ORKA Buy/$45 after Oruka📰that the FDA had cleared its IND application for its Phase 2a trial of ORKA-001 (the company's long-acting anti-IL-23p19 antibody) in moderate-to-severe PsO, called EVERLAST-A. $ABBV $PTGX - $JNJ #EDAV25 H.C. Wainwright said in its note: "This program is a randomized, double-blind, placebo-controlled Phase 2a trial designed to evaluate the safety and efficacy of a single dose level of ORKA-001 in moderate-to-severe psoriasis patients. EVERLAST-A will enroll approximately 80 patients, randomized 3:1 to receive ORKA-001 or matching placebo. The primary endpoint is PASI 100 at Week 16. ORKA-001 exposures are expected to match or exceed exposures in the KNOCKOUT study, providing a definitive test of whether higher exposures of an anti-IL-23p19 antibody can lead to greater efficacy. H.C. Wainwright went on to say:
0 · Reply
Quantumup
Quantumup Jul. 21 at 1:15 PM
Stifel reiterated $ORKA Buy-$47 after $ORKA's disclosure of the IND clearance for ORKA-001 and then catching up w/ mgmt.. $ABBV $PTGX $JNJ #EADV25 UCBJY $MLTX Stifel said in its note: "We caught up with management who noted that the IND clearance was based on interim Ph1 data (safety/tolerability) and Ph2a sites are open and actively enrolling -- Ph1 results to be presented at #EADV in September. Recall, ORKA-001 is a next-gen IL-23p19 which is designed to explore greater exposure and improved dosing vs. mega-blockbuster Skyrizi based on exploratory IST results in Psoriasis demonstrating superior efficacy/potential for remission in patients dosed with 4x the normal psoriasis dose (LINK). Meanwhile, $ORKA is on track to release Ph1 data for ORKA-002 (next-gen IL-17A/F mAb) by YE25 following a continued strong launch for Bimzelx and upcoming Ph3 data for $MLTX's sonelokimab -- there is currently limited investor focus on $ORKA as a player in the IL-17A/F space."
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 21 at 11:57 AM
$ORKA (+7.3% pre) Oruka Therapeutics Announces IND Clearance for EVERLAST-A - GN https://ooc.bz/l/70552
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 21 at 11:15 AM
$ORKA pt 17+
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 21 at 11:14 AM
$ORKA Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September By Oruka Therapeutics, Inc. | July 21, 2025, 7:00 AM
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 18 at 11:01 AM
$ORKA will need u 2 both today ! $SLS for the moves for stocks moving as we go through this !
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 18 at 11:00 AM
$BZAI coding off this 6.56 6.62 6.64 $SLS isolating now $ORKA indirectly cut an pasting old abio movement with 7.1-7.12 7.23* portions of old abio. @zsk78 u remember my abio dont u ? the pop but also the short !
0 · Reply
jlwnh
jlwnh Jul. 9 at 5:30 PM
$ORKA thants my boy!!!…
0 · Reply
Pika_Capital
Pika_Capital Jul. 9 at 5:18 PM
$ARWR $VRDN $ORKA $SYRE Pika's dumpster diving was quite successful 🤿
1 · Reply
jlwnh
jlwnh Jul. 8 at 2:27 PM
$ORKA hidden gem here…
0 · Reply
jlwnh
jlwnh Jul. 7 at 3:18 PM
$ORKA who had this from 7’s awesome run keep it up…
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 2 at 1:08 PM
$ORKA pm gapper
0 · Reply
Quantumup
Quantumup May. 22 at 12:17 PM
BTIG🏁 $ORKA Buy-$44 and said "Orukas pipeline has been carefully curated to improve on market-leading therapies in major IL-23- and IL-17-driven diseases." $PTGX $JNJ $ABBV BTIG added, "Consistent with other spin outs of Paragon Therapeutics (Private), Oruka leverages well-validated YTE modifications to focus on well-defined opportunities where optimized PK has high odds of translating to commercially-relevant improvements in adherence/convenience and potentially better efficacy, while not compromising safety. We expect Oruka's anti-IL-23 (ORKA-001) and anti-IL-17 (ORKA-002) mAbs to thrive as monotherapies and also potentially in combination (ORKA-021), as the targets have complimentary features that could support an ideal induction/maintenance efficacy profile. BTIG went on to say:
0 · Reply
WAYWARD_SUN
WAYWARD_SUN May. 20 at 4:30 PM
0 · Reply
WAYWARD_SUN
WAYWARD_SUN May. 15 at 7:32 PM
0 · Reply
Love_To_Learn
Love_To_Learn May. 13 at 10:46 AM
$BNRG hiding the 0.64 off the 8 spread now after the 0.62/064 2 spread why repkicatign my algo code i placed on $ORKA years ago b4 and after takign them 2 22pt then dropping them cut and pasting their 4.15-4.30 old trigger from 4 years ago +
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 25 at 4:59 PM
$ORKA also update pending
0 · Reply
Bug1
Bug1 Apr. 25 at 10:59 AM
$ORKA the proxy is out agm on june 2nd
0 · Reply
Pika_Capital
Pika_Capital Apr. 22 at 6:19 PM
$ARWR $VRDN $ORKA $SYRE so far so good
0 · Reply
Pika_Capital
Pika_Capital Apr. 9 at 5:46 PM
$ORKA +35% intraday reversal. Holy sh*t. I cant believe they brought it down below cash value
0 · Reply
_www_larval_com_
_www_larval_com_ Apr. 9 at 5:37 PM
$ORKA has soared 8% higher to 5% (~525Kv) a moment ago, 04/17 options, follow for more volatility.
0 · Reply
Pika_Capital
Pika_Capital Apr. 4 at 7:05 PM
Pika is too old to be shaken out of dev stage bios gamble basket. You sell, I BUY. Added chunks of $ARWR $VRDN $ORKA and $SYRE at these insane levels. Dev stage bios are trading as they are going COMPLETELY OUT OF BUSINESS lol 🤡 I will revisit this post in a year or so
1 · Reply